|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD
56.68 Billion
|
|
CAGR (2025-2030)
|
5.56%
|
|
Fastest Growing Segment
|
Innovative (Branded) Peptides
|
|
Largest Market
|
Midwest
|
|
Market Size (2030)
|
USD 77.54 Billion
|
Market Overview
United States Peptide Therapeutics
(Retail Side) Market was valued at USD 56.68 Billion in 2024 and is expected to
reach USD 77.54 Billion by 2030 with a CAGR of 5.56%. Peptide therapeutics are
short chains of amino acids that mimic natural biological processes, making
them highly specific and potent in treating a wide range of chronic and complex
conditions. These therapies are now widely available through retail pharmacies,
specialty pharmacies, and direct-to-patient distribution channels.
Market growth is primarily fueled by the
rising prevalence of diseases such as cancer, metabolic disorders, hormonal
deficiencies, and autoimmune conditions areas where peptide-based drugs have
shown high efficacy and safety. However, the market does face certain
challenges, including the high cost of peptide drugs, cold chain storage
requirements, and the complexity of large-scale peptide synthesis. These
factors can limit affordability and access in some segments of the population,
particularly where insurance coverage is limited.
Key Market Drivers
Growth
in Healthcare Industry
In 2023, U.S. healthcare spending rose by 7.5%,
reaching USD 4.9 trillion, or roughly USD 14,570 per capita. This expenditure
accounted for 17.6% of the nation’s Gross Domestic Product (GDP). The ongoing
expansion of the U.S. healthcare industry is a key driver accelerating the
growth of the peptide therapeutics market, particularly on the retail side. As
healthcare spending increases and access to outpatient and pharmacy-based
treatments improves, there is growing demand for effective, targeted therapies
that can be administered outside of hospital settings.
According to the Department of Health and Human
Services, approximately 129 million Americans live with at least one major
chronic condition. Notably, five of the top ten leading causes of death are
either preventable or closely associated with treatable chronic diseases. Peptide-based
drugs, known for their high specificity, low toxicity, and strong efficacy
profiles, are increasingly being prescribed for chronic conditions such as
cancer, diabetes, and metabolic disorders areas with rising prevalence across
the country. Furthermore, advancements in drug formulation and delivery
technologies have enhanced the stability and convenience of peptide
therapeutics, making them more suitable for retail distribution.
Surge
in Technological Advancements
The United States peptide therapeutics market on the
retail side is experiencing strong growth, largely driven by a surge in
technological advancements. Innovations in peptide synthesis, drug delivery
systems, and molecular engineering have significantly enhanced the stability,
bioavailability, and specificity of peptide-based drugs. AAPPTec, LLC is a
U.S.-based peptide synthesis company headquartered in Louisville, KY. The
company offers a comprehensive portfolio of peptide products, including
automated peptide synthesizers, peptide-related laboratory equipment, and
premium reagents. AAPPTec’s peptide synthesis solutions support chemists in the
efficient preparation and analysis of peptides for both semi-preparative and
preparative research applications.
Furthermore, improvements in formulation technologies,
including sustained-release injectables and transdermal delivery, are making
peptide drugs more patient-friendly, supporting broader acceptance and
compliance in outpatient settings. The integration of AI and machine learning
into peptide drug discovery is also accelerating R&D timelines, allowing
for faster commercialization. As a result, pharmaceutical companies are
expanding their retail portfolios with next-generation peptide therapies, making
technological innovation a key driver of market expansion.
Download Free Sample Report
Key Market Challenges
Manufacturing
and Stability Issues
Manufacturing and stability issues
present significant challenges to the United States Peptide Therapeutics Market
on the retail side. Peptide drugs are inherently complex molecules that require
precise synthesis processes, often involving multiple steps to ensure purity
and biological activity. The intricate nature of peptide manufacturing results
in high production costs and longer lead times, which can limit the scalability
and affordability of these therapies.
In addition to manufacturing
complexities, peptide therapeutics are sensitive to environmental conditions
such as temperature, pH, and light exposure. Maintaining their stability
throughout the supply chain from production to retail distribution and
ultimately patient use requires stringent cold chain logistics and specialized
storage conditions. Any deviation can lead to degradation, reduced efficacy, or
safety concerns, impacting patient outcomes and increasing the risk of product
recalls.
Key Market Trends
Surge
in Demand for GLP-1 Therapies
The United States peptide therapeutics
market, particularly on the retail side, is witnessing a significant surge in
demand for GLP-1 (glucagon-like peptide-1) therapies. This trend is primarily
driven by the growing prevalence of metabolic disorders such as type 2 diabetes
and obesity, conditions for which GLP-1 receptor agonists have demonstrated
considerable clinical efficacy. Over 38 million Americans approximately one in ten, are
affected by diabetes, with 90% to 95% diagnosed with type 2 diabetes. While
type 2 diabetes primarily develops in individuals aged 45 and older, its
prevalence is increasingly rising among children, adolescents, and young
adults.
GLP-1 therapies have gained substantial
traction due to their ability to regulate blood glucose levels, promote weight
loss, and improve cardiovascular outcomes. As healthcare providers increasingly
adopt these peptide-based treatments, retail pharmacies and specialty outlets
are experiencing heightened consumer interest and prescription volumes. The
rising demand is also fueled by advancements in formulation technologies,
leading to more patient-friendly delivery systems such as once-weekly
injections, which enhance adherence and overall patient outcomes.
Segmental Insights
Type Insights
Based on Type, Innovative (Branded)
Peptides have emerged as the fastest growing segment in the United States Peptide
Therapeutics (Retail Side) Market in 2024. This is due to their superior
efficacy, targeted mechanisms of action, and strong intellectual property
protection. These branded peptides often represent breakthrough therapies
addressing unmet medical needs in areas such as oncology, endocrinology, and
metabolic disorders. Their development is supported by significant investments
in research and development, resulting in advanced formulations that offer
improved stability, bioavailability, and patient compliance.
Indication
Insights
Based on Indication, Type 2 Diabetes have
emerged as the fastest growing segment in the United States Peptide
Therapeutics (Retail Side) Market during the forecast period. This is due to
several important factors. The increasing prevalence of Type 2 Diabetes in the
U.S., driven by lifestyle changes, obesity, and aging populations, has created
a substantial demand for effective and innovative treatment options. Peptide
therapeutics, particularly GLP-1 receptor agonists, have demonstrated
significant benefits in managing blood glucose levels, promoting weight loss,
and reducing cardiovascular risks, making them highly attractive to both
patients and healthcare providers.
Download Free Sample Report
Regional Insights
Based on Region, Midwest have emerged as
the dominating region in the United States Peptide Therapeutics (Retail Side)
Market in 2024. This is due to a combination of strategic advantages. The
region is home to a robust pharmaceutical manufacturing hub, supported by
well-established biotechnological research centers, which provide the necessary
infrastructure and expertise for the production and distribution of peptide
therapeutics. Its central geographic location offers logistical benefits,
enabling efficient and cost-effective distribution across the country.
Recent Development
- In July 2025, BioDuro, a global CRDMO,
and Atombeat Inc., a leader in AI-driven drug discovery, announced a strategic
partnership to develop an AI-powered platform for accelerated peptide drug
discovery. Combining Atombeat’s AI modeling and data-driven design with
BioDuro’s expertise in chemistry, biology, and DMPK, the platform enables a
seamless workflow from molecular design to preclinical candidate. This aims to
deliver high-quality cyclic peptides faster and more cost-effectively across
multiple therapeutic areas. Atombeat’s proprietary Hermite software and RiDYMO
platform leverage advanced technologies such as Reinforced Dynamics, Uni-Dock,
Uni-FEP, and Uni-QSAR to drive innovation.
- In May 2024, PeptiDream Inc., a publicly
listed biopharmaceutical company headquartered in Kanagawa, Japan, announced
the initiation of a strategic collaboration with Merck & Co., Inc., based
in Rahway, New Jersey, USA. This partnership focuses on the discovery and
development of innovative peptide therapeutics designed to effectively
neutralize the current SARS-CoV-2 virus responsible for COVID-19, as well as to
address potential future coronavirus outbreaks. Leveraging PeptiDream’s
proprietary peptide drug discovery platform alongside Merck’s extensive
expertise in infectious disease research and development, the collaboration
aims to accelerate the creation of next-generation antiviral therapies to meet
ongoing and emerging global health challenges.
- In October 2024, Amneal Pharmaceuticals,
Inc., a global pharmaceutical company, and Metsera, Inc., a clinical-stage
biopharmaceutical firm focused on advancing next-generation treatments for
obesity and metabolic diseases, announced a collaboration agreement to
facilitate the efficient development and large-scale global supply of a
portfolio of novel weight loss therapies. Metsera is advancing a pipeline of
innovative therapies, including ultra-long-acting injectable and oral
nutrient-stimulated hormone (NuSH) analogs and combination treatments, designed
with best-in-class profiles. Leveraging a proprietary library of over 20,000
NuSH peptide analogs and peptide/antibody conjugates, Metsera aims to meet the
growing demand and evolving needs within the global obesity and diabetes
markets through a broad range of therapeutic modalities.
- In January 2025, responding to the
increasing demand for peptide therapeutics, Cytovance Biologics and PolyPeptide
announced an expanded partnership. This collaboration leverages Cytovance’s
expertise in microbial and mammalian expression, process development, and cGMP
manufacturing alongside PolyPeptide’s capabilities in complex peptide
development and production. Having previously collaborated on select customer
projects, the companies are now broadening their partnership to offer drug
developers enhanced capacity, accelerated scale-up, and improved operational
efficiency supporting the rapid advancement of new peptide candidates from
development through to clinical and commercial stages.
Key Market Players
- CVS
Health
- Walgreens
Boots Alliance, Inc.
- Walmart
Pharmacy
- Rite
Aid Corp
- The
Kroger Co.
- Albertsons
- Costco
Wholesale Corporation
- Meijer,
Inc.
- Hims
& Hers Health, Inc.
- Lemonaid
Health, Inc.
|
By Type
|
By Indication
|
By Region
|
- Innovative (Branded) Peptides
- Biosimilar Peptides
- Generic Peptides
- Others
|
- Type 2 Diabetes
- Obesity/Weight Management
- Neuroendocrine Tumors
- Acromegaly
- Growth Hormone Deficiency
- Others
|
- Northeast
- Midwest
- South
- West
|
Report Scope
In this report, the United States Peptide
Therapeutics (Retail Side) Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- United States Peptide
Therapeutics (Retail Side) Market, By Type:
o Innovative (Branded) Peptides
o Biosimilar Peptides
o Generic Peptides
o Others
- United States Peptide
Therapeutics (Retail Side) Market, By Indication:
o Type 2 Diabetes
o Obesity/Weight Management
o Neuroendocrine Tumors
o Acromegaly
o Growth Hormone Deficiency
o Others
- United States Peptide
Therapeutics (Retail Side) Market, By Region:
o Northeast
o Midwest
o South
o West
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the United States Peptide Therapeutics (Retail Side) Market.
Available Customizations:
United States Peptide Therapeutics (Retail Side)
Market report with the given market data, TechSci Research offers
customizations according to a company's specific needs. The following
customization options are available for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
United States Peptide
Therapeutics (Retail Side) Market is an upcoming report to be released soon. If
you wish an early delivery of this report or want to confirm the date of
release, please contact us at [email protected]